Trials / Completed
CompletedNCT00659178
Combination Study Of SB-485232 (Interleukin 18) And Doxil For Advanced Stage Epithelial Ovarian Cancer
A Phase I, Dose Escalation Study to Assess the Safety & Biological Activity of Interleukin 18 (SB-485232) Administered by IV Infusion in Combination With Pegylated Liposomal Doxorubicin (Doxil) in Advanced Stage Epithelial Ovarian Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to identify a dose of SB-485232 which is safe, tolerable and biologically active when used in combination with pegylated liposomal doxorubicin (Doxil) in patients with epithelial ovarian cancer. This study will use a standard treatment regimen of pegylated liposomal doxorubicin (Doxil) in combination with rising doses of SB-485232. The dose selected from this study will be used in a future studies to evaluate the efficacy of this combination.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SB-485232 (interleukin 18), pegylated liposomal doxorubicin | SB-485232 (interleukin 18), pegylated liposomal doxorubicin |
Timeline
- Start date
- 2008-06-18
- Primary completion
- 2011-02-18
- Completion
- 2011-02-18
- First posted
- 2008-04-16
- Last updated
- 2017-07-21
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00659178. Inclusion in this directory is not an endorsement.